Currax Pharmaceuticals' New Study Confirms Safety of Weight Loss Drug CONTRAVE®/MYSIMBA® Currax Pharmaceuticals has published new evidence highlighting the cardiovascular safety of its weight loss medication CONTRAVE®/MYSIMBA®, reinforcing its efficacy in treating obesity.

Currax Pharmaceuticals' New Study Confirms Safety of Weight Loss Drug CONTRAVE®/MYSIMBA® #USA #Brentwood #Currax #CONTRAVE #MYSIMBA

Angripe slankemedisinene, er det for å ramme #Danmark?
#Ozempic
#Wegovy
#Mysimba

Currax Pharmaceuticals Achieves Remarkable Financial Growth and Operational Milestones for 2024 Currax Pharmaceuticals has reported exceptional results in 2024, including over 50% revenue growth, strategic operational advancements, and a global expansion in demand for its products.

Currax Pharmaceuticals Achieves Remarkable Financial Growth and Operational Milestones for 2024 #United_States #Brentwood #CONTRAVE #Currax_Pharmaceuticals #MYSIMBA